TITLE

Golimumab

AUTHOR(S)
Cada, Dennis J.; Levien, Terri L.; Baker, Danial E.
PUB. DATE
October 2009
SOURCE
Hospital Pharmacy;Oct2009, Vol. 44 Issue 10, p894
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/ nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topids pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The October 2009 monograph topics are fentanyl buccal soluble film, laromustine, paliperidone injection, saxagliptin, and trepostinil inhalation. The DUE is on fentanyl soluble film.
ACCESSION #
44994850

 

Related Articles

  • Golimumab.  // Australian Prescriber;Feb2010, Vol. 33 Issue 1, p23 

    The article discusses Golimumab, a new drug released in the Australian pharmaceutical market with approved use in the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is described as a recombinant human monoclonal antibody that blocks the activity of tumour...

  • Golimumab: a guide to its use in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.  // Drugs & Therapy Perspectives;Apr2010, Vol. 26 Issue 4, p1 

    The article discusses the pharmacodynamics of the drug golimumab. Golimumab has been approved by the European Union (EU) for the treatment of various automimmune diseases including rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. The drug is an immunoglobulin G1 (IgG1)...

  • Single-use autoinjector pen for etanercept.  // British Journal of Hospital Medicine (17508460);Oct2009, Vol. 70 Issue 10, p557 

    The article reports on the new drug preparation for Enbrel or etanercept, a biological treatment for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis, in Great Britain. It states that etanercept can be administered through an easyto- use pre-filled autoinjector...

  • COST OF TREATMENT OF RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS WITH BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE PERIOD 2013-2014 IN BULGARIA. BOYADZHIEVA, V. L.; STOILOV, N.; STOILOV, R.; PETROVA, G.; STEFANOV, S.; MEDJIDIEVA, D. // Journal of the Balkan Tribological Association;2016, Vol. 22 Issue 1, p391 

    In recent years in Bulgaria there is a tendency for an increase in costs for biological treatment of inflammatory joint diseases - rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). In 2013, according to the National Health Insurance Fund (NHIF) 5% of patients...

  • Anti-Tumour Necrosis Factor-α Therapy for Rheumatoid and Other Inflammatory Arthropathies: Update on Safety in Older Patients. Ornetti, Paul; Chevillotte, Hélène; Zerrak, Amal; Maillefert, Jean Francis // Drugs & Aging;2006, Vol. 23 Issue 11, p855 

    Anti-tumour necrosis factor (TNF)-α represents a major advance in the treatment of rheumatoid arthritis (RA), ankylosing spondylitis and psoriatic arthritis. It is usually well tolerated, but a potential increase in the incidence of some infections in patients taking anti-TNFα agents has...

  • Methotrexate and Hepatic Toxicity in Rheumatoid Arthritis and Psoriatic Arthritis. Tilling, Lindsey; Townsend, Sue; David, Joel // Clinical Drug Investigation;2006, Vol. 26 Issue 2, p55 

    Background: We set out in this study to demonstrate the adverse effect profile of methotrexate when used in the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in a district general hospital population, and to investigate the effect of alcohol consumption in these patients....

  • Simponi.  // Pharmaceutical Representative;Jul2009, Vol. 39 Issue 7, p11 

    The article reports on the U.S. Food and Drug Administration's (FDA's) approval of Simponi (golimumab) from Centocor Ortho Biotech Inc. It notes that the drug treats rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis. It is considered as the first...

  • J&J: Simponi's triple US approval could be first step towards blockbuster status.  // PharmaWatch: Monthly Review;Jun2009, Vol. 8 Issue 6, p21 

    In this article the author discusses the approval of Simponi (golimumab) from Centocor Ortho Biotech Inc. by the U.S. Food and Drug Administration (FDA). It is a new tumor necrosis factor (TNF) inhibitor for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. He mentions that...

  • Centocor and Schering-Plough win Canadian approval for arthritis drug.  // PharmaWatch: Biotechnology;Nov2009, Vol. 8 Issue 11, p17 

    The article reports that Health Canada has granted approval of Simponi as therapy for active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), and active ankylosing spondylitis (AS) by Centocor Ortho Biotech Inc. and Schering-Plough Corp. The approval of the drug is based from five...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics